Gaston Geenslaan 1
110 articles about ThromboGenics NV
BioSpace Movers and Shakers Nov. 5
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
ThromboGenics Business Update – H1 2018
Positive Topline Results for Diabetic Eye Disease Portfolio
ThromboGenics becomes “Oxurion”
Shareholders approve new name which better reflects the Company’s ambition to deliver best in class therapies for back of the eye disorders
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
ThromboGenics NV announces its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
ThromboGenics NV announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)
ThromboGenics NV announces that it has successfully enrolled the first patient in a Phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis®, Novartis), for the treatment of DME (NCT03499223).
Resources redirected to progress new drug candidates to clinic in H1 2018.
ThromboGenics Strengthens Leadership Team - Susan Schneider, MD Appointed Chief Medical Officer and Vinciane Vangeersdaele Appointed Chief Commercial Officer
Both will be members of the Company's executive team reporting to ThromboGenics' CEO, and they will operate from the Company's offices in Leuven, Belgium and Iselin, New Jersey, US.
ThromboGenics Business Update - Q3 2017
ThromboGenics issues a business update for the three-month period ending 30 September 2017.
ThromboGenics NV Announces Publication In Experimental Eye Research Of Preclinical Data Supporting Therapeutic Potential Of THR-317 In DR
ThromboGenics NV Presenting THR-687 Preclinical Data At European Association For Vision And Eye Research (EVER) Meeting
ThromboGenics NV Successfully Introduces New 'Already-Diluted' Formulation Of JETREA (Ocriplasmin) In The U.S.
Novartis AG Returns Global Eye Drug Rights To ThromboGenics NV
ThromboGenics NV Business Update - H1 2017
New ThromboGenics NV’ Ocriplasmin Clinical And Health Economic Data Presented At ASRS 2017 Annual Scientific Meeting In Boston
New ThromboGenics NV' Ocriplasmin Clinical And Health Economic Data Presented At ASRS 2017 Annual Scientific Meeting In Boston
ThromboGenics NV And BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement
ThromboGenics NV Long-Time Non-Executive Director Thomas Clay Appointed Chairman Of The Board Of Directors
ThromboGenics NV To Present The Industry Pipeline Of DME Treatments At Upcoming European Society Of Ophthalmology Congress, Barcelona, Spain
ThromboGenics NV To Present THR-317 Pre-Clinical Research Findings At The European Association For The Study Of Diabetes, Eye Complications Study Group (EASDec) Meeting In Budapest, Hungary